Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication in adult patients. It is marketed in the European Union and indicated for adult patients.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets.

Klacid (clarithromycin) is a macrolide antibiotic used to treat bacterial infections in several organ systems. - Community‑acquired pneumonia: eradicates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms. - Acute exacerbations of chronic bronchitis: shortens symptom duration and helps prevent further lung damage. - Skin and soft‑tissue infections: clears bacterial pathogens from dermal and subdermal tissues. - Helicobacter pylori eradication (in combination therapy): contributes to successful bacterial clearance when used with other agents.

Clarithromycin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose, watery stools. - Abdominal pain: cramping or discomfort in the abdomen. - Taste disturbance: altered or metallic taste sensation.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes. - QT prolongation: cardiac rhythm changes that may lead to arrhythmia. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing clarithromycin, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: avoid use in patients with severe hepatic impairment. - Review cardiac history: caution in individuals with known QT prolongation or electrolyte disturbances. - Monitor for drug‑induced diarrhea: discontinue if severe or persistent. - Evaluate concomitant medications: avoid combinations that may increase clarithromycin levels. - Pregnancy and lactation: use only if the potential benefit outweighs the risk; consult obstetric guidance. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Clarithromycin interacts with several medicines through metabolic pathways and transporter inhibition.

Major Interactions (Avoid): - Simvastatin: increased risk of myopathy; avoid co‑administration. - Pimozide: elevated plasma levels may cause serious cardiac effects. - Ergot alkaloids: risk of severe vasospasm; contraindicated.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: possible increase in serum concentration; observe for toxicity. - Carbamazepine: reduced carbamazepine levels; adjust dosage if needed.